Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- adverse events (AE)'s
研究概览
简要总结
Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.
详细描述
Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histology: Diagnosis of aggressive CD20+, confirmed by an excisional biopsy of a lymph node or by a sufficiently extensive biopsy of an extranodal involvement if there is no lymph node involvement. It will be possible to treat the following entities in this study as defined by the new WHO classification of 2008: B-NHL, Follicular lymphoma grade IIIb,DLBCL, not otherwise specified (NOS),common morphologic variants: centroblastic,immunoblastic,anaplastic,rare morphologic variants.DLBCL subtypes/entities:T cell/histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmoblastic lymphoma, Primary effusion lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Hodgkin lymphoma
- •Stage: Any stages according to Ann Arbor Classification
- •Risk group: All risk groups (IPI 1 to 5)
- •Life expectancy Life expectancy of at least 6 weeks, when lymphoma is treated
- •Age: Age elder than 81 or Age 61 to 80 and CIRS >6 not qualifying for CHOP-therapy
- •Gender: any
- •Performance status: Performance status ECOG 0 -
- •The performance status of each patient is to be assessed at the time of registration which might be after the initiation of pre-phase treatment which, as experience has shown, can result in a significant improvement of the patient´s performance status. A definition of the performance status is provided in Appendix 25.6
- •Ability to give informed consent
- •Written informed consent of the patient
- •Contract of participation signed by the study center and sponsor
排除标准
- •Already initiated lymphoma therapy (except for the prephase treatment until first application of rituximab)
- •Serious accompanying disorder or impaired organ function (except when due to lymphoma involvement), in particular: Heart: angina pectoris CCS >2, cardiac failure NYHA >3; Lungs: the patient is to be excluded if the resultant pulmonary function test shows FEV1<50% or a diffusion capacity <50% of the reference values: Calculated creatinin clearance < 10 ml/min (Cockcroft-Gault); Liver: total bilirubin > 3 mg/dl; Uncontrollable diabetes mellitus (because of prephase treatment with prednisone!)
- •Platelets <100 000/mm3, leukocytes <2500/mm3 (if not due to lymphoma)
- •Known hypersensitivity to the medications to be used
- •HIV-positivity
- •Acute or chronic active hepatitis
- •Poor patient compliance
- •Simultaneous participation in other treatment studies
- •Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic drugs for previous disorder
- •Other concomitant tumor disease and/or tumor disease in the past 5 years (except basalioma of the skin and carcinoma in situ)
- •CNS involvement of lymphoma (intracerebral, meningeal, intraspinal)
- •Active serious infections not controlled by oral or intravenous antibiotics or anti-fungal
- •Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities.
- •Non-conformity to eligibility criteria.
研究组 & 干预措施
Bendamustine and subcutaneous Rituximab
single-arm non randomized
干预措施: Bendamustine and subcutaneous rituximab (Drug)
结局指标
主要结局
adverse events (AE)'s
时间窗: up to 30 days after last study drug administration
protocol adherence
时间窗: 18 weeks after start of therapy
Progression-free survival
时间窗: 2 years
rate of therapy-associated deaths
时间窗: up to 30 days after last study drug administration
serious adverse events (SAE)'s
时间窗: up to 30 days after last study drug administration
次要结局
- Quality of life(2 years)
- PR rate(2 years)
- rate of primary progression(2 years)
- Comprehensive Geriatric Assessment(2 years)
- CR rate(2 years)
- relapse rate(2 years)
- event-free survival(2 years)
- overall survival(2 years)
研究者
Lorenz, Trümper, MD
Prof. Dr.
University of Göttingen